Status In progress
Process STA 2018
ID number 1268

Provisional Schedule

Final appraisal document 18 September 2019 - 02 October 2019
Expected publication 16 October 2019

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Consultees

Companies sponsors Shire Pharmaceuticals (lanadelumab)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups HAE UK Patient Support
Professional groups British Association of Dermatologists
  Royal College of Pathologists
  Royal College of Physicians
  United Kingdom Primary Immunodeficiency Network

Commentators

Comparator companies A A H Pharmaceuticals (danazol) - confidentiality agreement not signed, not participating
  Alliance Healthcare (danazol) - confidentiality agreement not signed, not participating
  Mylan (danazol) - confidentiality agreement not signed, not participating
  Sanofi (danazol) - confidentiality agreement not signed, not participating
  Sigma Pharmaceuticals (danazol) - confidentiality agreement signed, not participating
  CSL Behring (berinert) confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
07 August 2019 Committee meeting: 2
28 June 2019 - 19 July 2019 Appraisal consultation
06 June 2019 Committee meeting: 1
08 October 2018 In progress, In progress
08 October 2018 Invitation to participate
14 May 2018 (14:00) Scoping workshop (Manchester)
21 March 2018 - 20 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance